Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Operating Leases: 2019-2024

Historic Operating Leases for KalVista Pharmaceuticals (KALV) over the last 2 years, with Dec 2024 value amounting to $4.4 million.

  • KalVista Pharmaceuticals' Operating Leases was N/A to $4.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $4.4 million, marking a year-over-year change of. This contributed to the annual value of $6.0 million for FY2024, which is N/A change from last year.
  • As of Q4 2024, KalVista Pharmaceuticals' Operating Leases stood at $4.4 million, which was down 5.09% from $4.7 million recorded in Q4 2024.
  • In the past 5 years, KalVista Pharmaceuticals' Operating Leases ranged from a high of $6.9 million in Q3 2023 and a low of $926,000 during Q1 2020.
  • For the 2-year period, KalVista Pharmaceuticals' Operating Leases averaged around $5.7 million, with its median value being $6.0 million (2024).
  • Its Operating Leases has fluctuated over the past 5 years, first grew by 21.27% in 2021, then decreased by 28.58% in 2024.
  • Quarterly analysis of 4 years shows KalVista Pharmaceuticals' Operating Leases stood at $932,000 in 2020, then grew by 21.27% to $1.1 million in 2021, then reached $6.5 million in 2023, then declined by 28.58% to $4.4 million in 2024.
  • Its Operating Leases stands at $4.4 million for Q4 2024, versus $4.7 million for Q4 2024 and $5.0 million for Q3 2024.